C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.
The Critical Path Institute's Translational Therapeutics Accelerator (TRxA) is a not-for-profit drug accelerator aimed at helping academic researchers turn new therapeutic ideas into viable drug candidates. This initiative focuses on the early stages of drug development, offering resources, strategic guidance, and engagement with contract research organizations to develop comprehensive data packages essential for attracting biotech and pharmaceutical company investment. TRxA specifically supports projects from early lead optimization through to Investigational New Drug (IND)-enabling studies of small molecule therapeutics, excluding biologics, drug repurposing initiatives, diagnostics, and medical devices. The TRxA BRIDGe Awards target faculty at universities and nonprofit institutions worldwide, without restriction to specific therapeutic areas, covering three stages of drug development from optimization to IND enabling studies.